Category Archives: Platelet Rich Plasma Injections


Stem Cell Clinic > Platelet Rich Plasma Injections

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

By Platelet Rich Plasma Injections

MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results and provide a business update for its first quarter 2025 ended February 28 on Wednesday, April 9, 2025, at 8:30 a.m. ET.

Go here to see the original:
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

Praxis Precision Medicines to Participate in Upcoming April Conferences

By Platelet Rich Plasma Injections

BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this April:

Read this article:
Praxis Precision Medicines to Participate in Upcoming April Conferences

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN)…

By Platelet Rich Plasma Injections

Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points

Read more from the original source:
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN)...

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

By Platelet Rich Plasma Injections

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its products in relation to the U.S. Government’s announcement on tariffs for imported products. Mesoblast believes that its allogeneic cellular products, including Ryoncil® and Revascor®, will not be subject to the tariffs.

See the original post:
Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

New LabTAG Add-On Streamlines Laboratory Labeling with Dymo® LabelWriter™ 5-Series and eLabNext Integration

By Platelet Rich Plasma Injections

BOSTON, April 04, 2025 (GLOBE NEWSWIRE) --  GA International, a global leader in laboratory identification solutions, under its LabTAG brand, announced today that its DYMO® LabelWriter™ 5-Series Printing Kits are now compatible with eLabNext’s Digital Lab Platform (DLP) — an intuitive and flexible system for collecting, managing, and analyzing laboratory information.

See the rest here:
New LabTAG Add-On Streamlines Laboratory Labeling with Dymo® LabelWriter™ 5-Series and eLabNext Integration

Dogecoin Cash, Inc. Subsidiary PrestoDoctor Launches April Promotion Offering 42.0% Off Medical Cannabis Evaluations

By Platelet Rich Plasma Injections

MESQUITE, NV, April 04, 2025 (GLOBE NEWSWIRE) -- Mesquite, NV — Dogecoin Cash, Inc. (OTCIQ: CBDS), is pleased to announce that its subsidiary, PrestoDoctor (www.prestodoctor.com), is rolling out a limited-time April promotion offering 42.0% off medical cannabis card evaluations and renewals throughout the month of April, our largest ever discount.

Read the original post:
Dogecoin Cash, Inc. Subsidiary PrestoDoctor Launches April Promotion Offering 42.0% Off Medical Cannabis Evaluations

Verano to Report First Quarter 2025 Financial Results on May 8, 2025

By Platelet Rich Plasma Injections

CHICAGO, April 04, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial results for the first quarter ended March 31, 2025, before the market opens on May 8, 2025.

Read the original post:
Verano to Report First Quarter 2025 Financial Results on May 8, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Platelet Rich Plasma Injections

RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,500 shares of BioCryst common stock. The RSUs were granted as of April 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more here:
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

→←